SCHEMBL13833709

SCHEMBL13833709

CC(=O)Nc1nc2cnccc2cc1-c1nc2ccccc2s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.55
▸ MAPT P10636 5/20 0.55
▸ RAB9A P51151 4/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ HPGD P15428 1/20 0.52
▸ NPC1 O15118 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ GAA P10253 1/20 0.51
▸ DYRK1A Q13627 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ ADORA1 P30542 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CYP3A4 P08684 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.43
▸ THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13833632 0.82 KDM4E (0.58) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL9042466 0.76 KDM4E (0.81) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL13735857 0.72 POLB (0.58) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL13833778 0.72 POLB (0.58) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL5667542 0.71 KDM4E (0.65) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL2246115 0.71 MAPT (1.00) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL5668385 0.70 KDM4E (0.63) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL5615796 0.69 KDM4E (0.62) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL29636830 0.68 RAB9A (0.74) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL7105704 0.68 RAB9A (0.74) KDM4EMAPTRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 — — US disclosed
WO-2012154888-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP KDM4E 3155/4885MAPT 221/4885RAB9A 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback